Literature DB >> 8471610

Glycosphingolipid backbone conformation and behavior in cholesterol-containing phospholipid bilayers.

K S Hamilton1, H C Jarrell, K M Brière, C W Grant.   

Abstract

2H NMR spectroscopy was used to consider correspondence between existing single-crystal X-ray data for glycosphingolipids and their ceramide backbone conformation in fluid phospholipid membranes. A monoglycosylated sphingolipid, glucosylceramide (GlcCer), which represents the core structure of many important glycosphingolipids, was derived by partial synthesis through replacement of all native fatty acids with the 18-carbon species, stearic acid, deuterated at C2. N-[2,2-2H2]stearoyl-GlcCer was used to probe glycosphingolipid orientation and motion at low concentration in "fluid" phospholipid bilayers composed of dimyristoylphosphatidylcholine (DMPC), with and without physiological amounts of cholesterol. Spectral analysis, aided by stereoselective monodeuteration of the GlcCer fatty acid at C2, demonstrated that glycosphingolipid average acyl chain backbone conformation in fluid phospholipid membranes, with or without cholesterol, is likely closely related to that predicted from single crystal X-ray studies [Pascher, I. (1976) Biochim. Biophys. Acta 455, 433-451; Pascher, I., & Sundell, S. (1977) Chem. Phys. Lipids 20, 175-191]. To test the generality of this observation, specific comparisons were made involving galactosylceramide (GalCer) and globoside. GalCer provided a glycolipid differing only in monosaccharide stereochemistry (galactose vs glucose). Globoside permitted isolation of the effect of headgroup size, since it is derived from GlcCer via extension of the carbohydrate portion by the oligosaccharide, GalNAc beta 1-->3Gal alpha 1-->4Gal attached in beta 1-->4 linkage to the Glc residue.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471610     DOI: 10.1021/bi00066a024

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Cholesterol decreases the interfacial elasticity and detergent solubility of sphingomyelins.

Authors:  X M Li; M M Momsen; J M Smaby; H L Brockman; R E Brown
Journal:  Biochemistry       Date:  2001-05-22       Impact factor: 3.162

2.  The 3-hydroxy group and 4,5-trans double bond of sphingomyelin are essential for modulation of galactosylceramide transmembrane asymmetry.

Authors:  Barbara Malewicz; Jacob T Valiyaveettil; Kochurani Jacob; Hoe-Sup Byun; Peter Mattjus; Wolfgang J Baumann; Robert Bittman; Rhoderick E Brown
Journal:  Biophys J       Date:  2005-01-14       Impact factor: 4.033

3.  2H and 13C nuclear magnetic resonance study of N-palmitoylgalactosylsphingosine (cerebroside)/cholesterol bilayers.

Authors:  M J Ruocco; D J Siminovitch; J R Long; S K Das Gupta; R G Griffin
Journal:  Biophys J       Date:  1996-10       Impact factor: 4.033

4.  The interfacial elastic packing interactions of galactosylceramides, sphingomyelins, and phosphatidylcholines.

Authors:  J M Smaby; V S Kulkarni; M Momsen; R E Brown
Journal:  Biophys J       Date:  1996-02       Impact factor: 4.033

5.  Cholesterol's interfacial interactions with sphingomyelins and phosphatidylcholines: hydrocarbon chain structure determines the magnitude of condensation.

Authors:  J M Smaby; H L Brockman; R E Brown
Journal:  Biochemistry       Date:  1994-08-09       Impact factor: 3.162

6.  Thermotropic behavior of galactosylceramides with cis-monoenoic fatty acyl chains.

Authors:  V S Kulkarni; R E Brown
Journal:  Biochim Biophys Acta       Date:  1998-07-17

7.  Glycosphingolipid headgroup orientation in fluid phospholipid/cholesterol membranes: similarity for a range of glycolipid fatty acids.

Authors:  M R Morrow; D M Singh; C W Grant
Journal:  Biophys J       Date:  1995-09       Impact factor: 4.033

Review 8.  Sphingolipid organization in biomembranes: what physical studies of model membranes reveal.

Authors:  R E Brown
Journal:  J Cell Sci       Date:  1998-01       Impact factor: 5.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.